Another weight loss drug approved
A combination of phentermine and topiramate extended-release (Qsymia) was recently approved by the FDA as an addition to a reduced-calorie diet and exercise for chronic weight management.
A combination of phentermine and topiramate extended-release (Qsymia) was recently approved by the FDA as an addition to a reduced-calorie diet and exercise for chronic weight management.
It is approved for adults with a body mass index (BMI) of 30 kg/m2 or greater or adults with a BMI of 27 kg/m2 or greater who have at least one weight-related condition such as diabetes. The drug must not be used during pregnancy or in patients with glaucoma or hyperthyroidism. The recommended daily dose contains 7.5 mg of phentermine and 46 mg of topiramate extended-release, but a higher dose (15 mg phentermine and 92 mg of topiramate extended-release) is available for select patients. It can increase heart rate, so regular monitoring of heart rate is recommended for all patients, especially when starting or increasing the dose.